Authorizes an individual to refuse certain medical treatments
HB 377 creates a new subpart in Louisiana law titled the “Right to Refuse Emergency Use Authorization Drugs Act.” The bill applies to medical devices, tests, pharmaceuticals, drugs, vaccines, and biological products that have received only Emergency Use Authorization from the U.S. Food and Drug Administration, and it is aimed at ensuring that individuals are fully informed of their right to refuse such products. It defines key terms such as “covered drug or vaccine,” “healthcare provider,” and “informed consent,” and frames the measure as an informed-consent and patient-choice law.
Under the bill, a healthcare provider must give both written and verbal notice before administering a covered product. That notice must explain that the product is only authorized through the EUA process, that the patient may refuse without discrimination or loss of services, and the known risks, benefits, and alternatives, including nonintervention. The provider must also offer a verbal explanation, answer questions, and obtain a signature or electronic acknowledgment that the notice was received; that acknowledgment is not itself consent. The bill further prohibits coercion or retaliation, requires documentation of a refusal in the medical record, and allows disciplinary action against providers who fail to comply.
The bill’s impact would be to add a specific statutory notice-and-refusal framework for EUA-only medical products in Title 40 of the Louisiana Revised Statutes. It would not eliminate informed consent generally, but it would impose additional disclosure, documentation, and acknowledgment requirements on healthcare providers and institutions administering EUA-authorized products. It also creates potential enforcement consequences through licensing authorities and complaint processes for patients who believe the requirements were violated.
The available context shows no committee transcript, recorded votes, or formal status actions, so there is no documented debate history to gauge legislative sentiment from the record provided. Based on the bill text alone, the measure appears to be driven by a strong patient-autonomy and anti-coercion theme, with an emphasis on disclosure and the right to decline treatment. Because no opposition testimony or vote history is included, specific points of contention are not documented here, though the most likely areas of dispute would be the bill’s special treatment of EUA products, the added compliance burden on providers, and the potential for disciplinary enforcement tied to refusal-notice procedures.
HB 377 would add R.S. 40:1162.1 through 1162.3 to Louisiana law, creating a specific legal regime for emergency-use-authorized medical devices, tests, drugs, vaccines, and biological products. It would require healthcare providers to give detailed notice, secure acknowledgment of receipt, document refusals, and avoid coercion or adverse consequences when a patient declines an EUA-only product. Providers who do not comply could face licensing discipline, fines, or other penalties from the appropriate authority.
No committee discussion or vote record is provided, so there is no direct evidence of legislative sentiment from debate or roll call. The bill’s language reflects a pro-consent, pro-refusal posture centered on patient autonomy, transparency, and protection from coercion. On its face, the measure is framed positively as an informed-consent safeguard rather than a restriction on care.
No specific points of contention are documented in the supplied materials because there are no transcripts or votes. Based on the bill’s structure, likely areas of disagreement would include whether EUA-only products should receive special statutory treatment, whether the notice requirements are redundant with existing informed-consent law, and whether the threat of disciplinary action against providers is appropriate. Potentially affected parties include hospitals, clinics, physicians, licensing boards, and patients receiving EUA-authorized treatments.